First derivative synchronous fluorescence spectroscopy for the determination of Gatifloxacin in presence of its oxidative degradation product: Application to pharmaceutical preparation

A highly accurate and precise spectrofluorimetric method was established for quantitation of Gatifloxacin in pure material, pharmaceutical formulations and in the existence of its oxidative degradation product. The emission was recorded at 487 nm after the excitation at 290 nm. Using micelle, sodium...

Full description

Saved in:
Bibliographic Details
Published inSpectrochimica acta. Part A, Molecular and biomolecular spectroscopy Vol. 206; pp. 302 - 313
Main Authors Salama, Fathy M.M., Attia, Khalid A.M., Said, Ragab A.M., El-Attar, Abdul-Aziz M.M.
Format Journal Article
LanguageEnglish
Published England Elsevier B.V 05.01.2019
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:A highly accurate and precise spectrofluorimetric method was established for quantitation of Gatifloxacin in pure material, pharmaceutical formulations and in the existence of its oxidative degradation product. The emission was recorded at 487 nm after the excitation at 290 nm. Using micelle, sodium dodecyl sulphate (SDS), enhanced fluorescence intensity of Gatifloxacin-SDS complex. The optimization of numerous experimental conditions was carried out. The improved emission showed a suitable linear correlation between derivative synchronous fluorescence power and concentration of Gatifloxacin over the range of 10 to 100 ng/mL with a determination coefficient equals 0.9996. Studying cytotoxicity and antimicrobial susceptibility for oxidative degradation product of Gatifloxacin was carried out using Gatifloxacin as a control. In comparison, the proposed method presented a superior sensitivity and enhanced stability over the reported method. [Display omitted] •Confirmation of Gatifloxacin degradation•Micelle, SDS, can improve the fluorescence intensity.•Solving the severely overlapped spectra•Antimicrobial and toxic effect of oxidative degradation product•Analysis of the pharmaceutical dosage form without the inference of excipients.
ISSN:1386-1425
1873-3557
DOI:10.1016/j.saa.2018.08.003